We have developed a new method to detect Alzheimer's disease and Parkinson's disease, using just a few microliters of blood or cerebrospinal fluid (CSF).

Our mission has two key goals:

Enhancing diagnostic pathways
We aim to deliver meaningful benefits to patients by improving how neurodegenerative diseases such as Parkinson’s and Alzheimer’s are diagnosed. Today, diagnosis often relies heavily on clinical evaluations, which can be time-consuming for clinicians and may vary from day to day. This can delay reaching a clear and reliable diagnosis.

Supporting therapeutic development
We strive to accelerate advances in drug development and disease management by providing tools for precise and objective staging of disease severity and progression. This enables accurate evaluation of treatment effects from the earliest stages of disease, independent of symptomatic therapies, and may also support more precise patient selection and stratification in clinical trials. Ultimately, we aim to improve patient care and outcomes by enabling the development of more effective therapies.